In vivo inhibition of neuropeptide FF agonism by BIBP3226, an NPY Y1 receptor antagonist

Peptides

Volumn 27, Issue 9, 2006, Pages 2207-2213

  Fang, Quan ^a   Guo, Jia ^a   He, Feng ^a   Peng, Ya li ^a   Chang, Min ^a   Wang, Rui ^a  

^a LANZHOU UNIVERSITY   (China)

Author keywords

Antagonist; BIBP3226; In vivo; Neuropeptide FF (NPFF); NPFF receptors

Indexed keywords

NALPHA (DIPHENYLACETYL) N (4 HYDROXYBENZYL) DEXTRO ARGININAMIDE; NEUROPEPTIDE; NEUROPEPTIDE FF; NEUROPEPTIDE FF RECEPTOR; NEUROPEPTIDE VF; NEUROPEPTIDE Y1 RECEPTOR; RECEPTOR; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG; URETHAN;

ANIMAL EXPERIMENT; ARTERIAL PRESSURE; ARTICLE; CONTROLLED STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TAIL FLICK TEST;

ANIMALS; ANTI-ANXIETY AGENTS; ARGININE; HYPOTHERMIA; MALE; MICE; OLIGOPEPTIDES; RATS; RATS, WISTAR; RECEPTORS, NEUROPEPTIDE; RECEPTORS, NEUROPEPTIDE Y; TACHYCARDIA; TIME FACTORS;

EID: 33746927952     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2006.04.002     Document Type: Article

References (39)

1. Allard M., Labrouche S., Nosjean A., and Laguzzi R. Mechanisms underlying the cardiovascular responses to peripheral administration of NPFF in the rat. J Pharmacol Exp Ther 274 (1995) 577-583
2. Bonini J.A., Jones K.A., Adham N., Forray C., Artymyshyn R., Durkin M.M., et al. Identification and characterization of two G protein-coupled receptors for neuropeptide FF. J Biol Chem 275 (2000) 39324-39331
3. Cabrele C., and Beck-Sickinger A.G. Molecular characterization of the ligand-receptor interaction of the neuropeptide Y family. J Pept Sci 6 (2000) 97-122
4. Desprat C., and Zajac J.M. Hypothermic effects of neuropeptide FF analogues in mice. Pharmacol Biochem Behav 58 (1997) 559-563
5. Doods H.N., Wieland H.A., Engel W., Eberlein W., Willim K.D., Entzeroth M., et al. BIBP 3226, the first selective neuropeptide Y1 receptor antagonist: a review of its pharmacological properties. Regul Pept 65 (1996) 71-77
6. 1 receptor antagonist BIBP 3226. J Pharmacol Exp Ther 275 (1995) 136-142
7. Elshourbagy N.A., Ames R.S., Fitzgerald L.R., Foley J.J., Chambers J.K., Szekeres P.G., et al. Receptor for the pain modulatory neuropeptides FF and AF is an orphan G protein-coupled receptor. J Biol Chem 275 (2000) 25965-25971
8. Engstrom M., Brandt A., Wurster S., Savola J.M., and Panula P. Prolactin releasing peptide has high affinity and efficacy at neuropeptide FF2 receptors. J Pharmacol Exp Ther 305 (2003) 825-832
9. 2 receptors. Peptides 24 (2003) 1947-1954
10. Fang Q., Guo J., Chang M., Chen L.X., Chen Q., and Wang R. Neuropeptide FF receptors exert contractile activity via inhibition of nitric oxide release in the mouse distal colon. Peptides 26 (2005) 791-797
11. Fang Q., Guo J., Peng Y.L., Chang M., He F., Chen Q., et al. In vitro and in vivo studies of dansylated compounds, the putative agonists and antagonists on neuropeptide FF receptors. Peptides 27 6 (2006) 1297-1304
12. Frances B., Lahlou H., and Zajac J.M. Cholera and pertussis toxins inhibit differently hypothermic and anti-opioid effects of neuropeptide FF. Regul Pept 98 (2001) 13-18
13. Haley T.J., and McCormick W.G. Pharmacological effects produced by intracerebral injections of drugs in the conscious mouse. Br J Pharmacol 12 (1957) 12-15
14. Hinuma S., Shintani Y., Fukusumi S., Iijima N., Matsumoto Y., Hosoya M., et al. New neuropeptides containing carboxy-terminal RFamide and their receptor in mammals. Nat Cell Biol 2 (2000) 703-708
15. Huang E.Y., Li J.Y., Tan P.P., Wong C.H., and Chen J.C. The cardiovascular effects of PFRFamide and PFR(Tic)amide, a possible agonist and antagonist of neuropeptide FF (NPFF). Peptides 21 (2000) 205-210
16. Jaszberenyi M., Bujdoso E., Kiss E., Pataki I., and Telegdy G. The role of NPY in the mediation of orexin-induced hypothermia. Regul Pept 104 (2002) 55-59
17. Lagerstrom M.C., Fredriksson R., Bjarnadottir T.K., Fridmanis D., Holmquist T., Andersson J., et al. Origin of the prolactin-releasing hormone (PRLH) receptors: evidence of coevolution between PRLH and a redundant neuropeptide Y receptor during vertebrate evolution. Genomics 85 (2005) 688-703
18. Liu Q., Guan X.M., Martin W.J., McDonald T.P., Clements M.K., Jiang Q., et al. Identification and characterization of novel mammalian neuropeptide FF-like peptides that attenuate morphine-induced antinociception. J Biol Chem 276 (2001) 36961-36969
19. Malin D.H., Lake J.R., Leyva J.E., Hammond M.V., Rogillio R.B., Arcangeli K.R., et al. Analog of neuropeptide FF attenuates morphine abstinence syndrome. Peptides 12 (1991) 1011-1014
20. Malin D.H., Lake J.R., Smith D.A., Jones J.A., Morel J., Claunch A.E., et al. Subcutaneous injection of an analog of neuropeptide FF prevents naloxone-precipitated morphine abstinence syndrome. Drug Alcohol Depend 40 (1995) 37-42
21. Mazarguil H., Gouarderes C., Tafani J.A., Marcus D., Kotani M., Mollereau C., et al. Structure-activity relationships of neuropeptide FF: role of C-terminal regions. Peptides 22 (2001) 1471-1478
22. 2 receptors of the NPY ligands GR231118 and BIBP3226. Br J Pharmacol 133 (2001) 1-4
23. 1 receptor antagonists. Eur J Pharmacol 451 (2002) 245-256
24. Parker E., Van Heek M., and Stamford A. Neuropeptide Y receptors as targets for anti-obesity drug development: perspective and current status. Eur J Pharmacol 440 (2002) 173-187
25. Picker M.J., Allen R.M., Morgan D., Levine A.S., O'Hare E., and Cleary J.P. Effects of neuropeptide Y on the discriminative stimulus and antinociceptive properties of morphine. Pharmacol Biochem Behav 64 (1999) 161-164
26. Prokai L., Prokai-Tatrai K., Zharikova A., Li X., and Rocca J.R. Combinatorial lead optimization of a neuropeptide FF antagonist. J Med Chem 44 (2001) 1623-1626
27. Quelven I., Roussin A., Burlet-Schiltz O., Gouarderes C., Tafani J.A., Mazarguil H., et al. Dissociation of pharmacological pro- and anti-opioid effects by neuropeptide FF analogs. Eur J Pharmacol 449 (2002) 91-98
28. Quelven I., Roussin A., and Zajac J.M. Comparison of pharmacological activities of neuropeptide FF1 and neuropeptide FF2 receptor agonists. Eur J Pharmacol 508 (2005) 107-114
29. Rosow C.E., Miller J.M., Pelikan E.W., and Cochin J. Opiates and thermoregulation in mice. I. Agonists. J Pharmacol Exp Ther 213 (1980) 273-283
30. 2 antiserum. Neuropeptides 10 (1987) 37-42
31. Roumy M., and Zajac J.M. Neuropeptide FF, pain and analgesia. Eur J Pharmacol 345 (1998) 1-11
32. Rudolf K., Eberlein W., Engel W., Wieland H.A., Willim K.D., Entzeroth M., et al. The first highly potent and selective non-peptide neuropeptide Y Y1 receptor antagonist: BIBP3226. Eur J Pharmacol 271 (1994) R11-R13
33. Silva A.P., Cavadas C., and Grouzmann E. Neuropeptide Y and its receptors as potential therapeutic drug targets. Clin Chim Acta 326 (2002) 3-25
34. Simonin F., Schmitt M., Laulin J.P., Laboureyras E., Jhamandas J.H., Mactavish D., et al. RF9, a potent and selective neuropeptide FF receptor antagonist, prevents opioid-induced tolerance associated with hyperalgesia. Proc Natl Acad Sci U S A 103 (2006) 466-471
35. Szekely M., Petervari E., Balasko M., Hernadi I., and Uzsoki B. Effects of orexins on energy balance and thermoregulation. Regul Pept 104 (2002) 47-53
36. Tan P.P., Chen J.C., Li J.Y., Liang K.W., Wong C.H., and Huang E.Y. Modulation of naloxone-precipitated morphine withdrawal syndromes in rats by neuropeptide FF analogs. Peptides 20 (1999) 1211-1217
37. Vilim F.S., Aarnisalo A.A., Nieminen M.L., Lintunen M., Karlstedt K., Kontinen V.K., et al. Gene for pain modulatory neuropeptide NPFF: induction in spinal cord by noxious stimuli. Mol Pharmacol 55 (1999) 804-811
38. Zhang Y., Lundeberg T., and Yu L. Involvement of neuropeptide Y and Y1 receptor in antinociception in nucleus raphe magnus of rats. Regul Pept 95 (2000) 109-113
39. Zukowska-Grojec Z., Haass M., and Bayorh M.A. Neuropeptide Y and peptide YY mediate nonadrenergic vasoconstriction and modulate sympathetic responses in rats. Regul Pept 15 (1986) 99-110